301 related articles for article (PubMed ID: 21907255)
1. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.
Saha A; Chowdhury MI; Khanam F; Bhuiyan MS; Chowdhury F; Khan AI; Khan IA; Clemens J; Ali M; Cravioto A; Qadri F
Vaccine; 2011 Oct; 29(46):8285-92. PubMed ID: 21907255
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
[TBL] [Abstract][Full Text] [Related]
3. Induction of systemic, mucosal and memory antibody responses targeting Vibrio cholerae O1 O-specific polysaccharide (OSP) in adults following oral vaccination with an oral killed whole cell cholera vaccine in Bangladesh.
Akter A; Dash P; Aktar A; Jahan SR; Afrin S; Basher SR; Hakim A; Lisa AK; Chowdhury F; Khan AI; Xu P; Charles RC; Kelly M; Kováč P; Harris JB; Bhuiyan TR; Calderwood SB; Ryan ET; Qadri F
PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007634. PubMed ID: 31369553
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.
Capeding MRZ; Gonzales MLAM; Dhingra MS; D'Cor NA; Midde VJ; Patnaik BN; Thollot Y; Desauziers E
Hum Vaccin Immunother; 2017 Oct; 13(10):2232-2239. PubMed ID: 28910563
[TBL] [Abstract][Full Text] [Related]
5. Comparison of O-specific polysaccharide responses in patients following infection with
Kaisar MH; Kelly M; Kamruzzaman M; Bhuiyan TR; Chowdhury F; Khan AI; LaRocque RC; Calderwood SB; Harris JB; Charles RC; Čížová A; Mečárová J; Korcová J; Bystrický S; Kováč P; Xu P; Qadri F; Ryan ET
mSphere; 2023 Oct; 8(5):e0025523. PubMed ID: 37646517
[TBL] [Abstract][Full Text] [Related]
6. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET
mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076
[TBL] [Abstract][Full Text] [Related]
7. A non-inferiority trial comparing two killed, whole cell, oral cholera vaccines (Cholvax vs. Shanchol) in Dhaka, Bangladesh.
Chowdhury F; Akter A; Bhuiyan TR; Tauheed I; Teshome S; Sil A; Park JY; Chon Y; Ferdous J; Basher SR; Ahmed F; Karim M; Ahasan MM; Mia MR; Masud MMI; Khan AW; Billah M; Nahar Z; Khan I; Ross AG; Kim DR; Ashik MMR; Digilio L; Lynch J; Excler JL; Clemens JD; Qadri F
Vaccine; 2022 Jan; 40(4):640-649. PubMed ID: 34969541
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study to evaluate safety, tolerability and immunogenicity of Hillchol®, an inactivated single Hikojima strain based oral cholera vaccine, in a sequentially age descending population in Bangladesh.
Chowdhury F; Ali Syed K; Akter A; Rahman Bhuiyan T; Tauheed I; Khaton F; Biswas R; Ferdous J; Al Banna H; Ross AG; Mc Millan N; Sharma T; Kanchan V; Pal Singh A; Gill D; Lebens M; Nordqvist S; Holmgren J; Clemens JD; Qadri F
Vaccine; 2021 Jul; 39(32):4450-4457. PubMed ID: 34218960
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the immunogenicity and safety of Euvichol-Plus with Shanchol in healthy Indian adults and children: an open-label, randomised, multicentre, non-inferiority, parallel-group, phase 3 trial.
Shah S; Nandy RK; Sethi SS; Chavan B; Pathak S; Dutta S; Rai S; Singh C; Chayal V; Patel C; Kumar NR; Chavan AT; Chawla A; Singh A; Roy AK; Singh N; Baik YO; Lee Y; Park Y; Jeong KH; Ahmed S
Lancet Reg Health Southeast Asia; 2023 Dec; 19():100256. PubMed ID: 38076719
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Song KR; Chapagain RH; Tamrakar D; Shrestha R; Kanodia P; Chaudhary S; Wartel TA; Yang JS; Kim DR; Lee J; Park EL; Cho H; Lee J; Thaisrivichai P; Vemula S; Kim BM; Gupta B; Saluja T; Pansuriya RK; Ganapathy R; Baik YO; Lee YJ; Jeon S; Park Y; Her HL; Park Y; Lynch JA
Lancet Glob Health; 2024 May; 12(5):e826-e837. PubMed ID: 38614631
[TBL] [Abstract][Full Text] [Related]
11. [Tolerance and immunogenicity of an oral dose of CVD 103-HgR, a live attenuated Vibrio cholerae 01 strain: a double-blind study of Chilean adults].
Lagos R; Avendaño A; Horwitz I; Prado V; Ferreccio C; Sotomayor V; Losonsky G; Wasserman SS; Cryz S; Kaper JB
Rev Med Chil; 1993 Aug; 121(8):857-63. PubMed ID: 8296092
[TBL] [Abstract][Full Text] [Related]
12. Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone.
Kanungo S; Desai SN; Nandy RK; Bhattacharya MK; Kim DR; Sinha A; Mahapatra T; Yang JS; Lopez AL; Manna B; Bannerjee B; Ali M; Dhingra MS; Chandra AM; Clemens JD; Sur D; Wierzba TF
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003574. PubMed ID: 25764513
[TBL] [Abstract][Full Text] [Related]
13. Immune responses following killed whole vibrio-B subunit oral cholera vaccine in human volunteers.
Pitisuttithum P; Migasena S; Suntharasamai P; Supanaranond W; Desakorn V; Prayurahong B
Southeast Asian J Trop Med Public Health; 1989 Jun; 20(2):201-5. PubMed ID: 2609209
[TBL] [Abstract][Full Text] [Related]
14. Impaired immune response to natural infection as a correlate of vaccine failure in a field trial of killed oral cholera vaccines.
Clemens J; Rao M; Sack D; Ahmed F; Khan MR; Chakraborty J; Kay B; Huda S; Yunus M; van Loon F
Am J Epidemiol; 1995 Oct; 142(7):759-64. PubMed ID: 7572947
[TBL] [Abstract][Full Text] [Related]
15. Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine.
Chowdhury F; Bhuiyan TR; Akter A; Bhuiyan MS; Khan AI; Tauheed I; Ahmed T; Ferdous J; Dash P; Basher SR; Hakim A; Lynch J; Kim JH; Excler JL; Kim DR; Clemens JD; Qadri F
Vaccine; 2020 Feb; 38(7):1753-1761. PubMed ID: 31879124
[TBL] [Abstract][Full Text] [Related]
16. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera.
Alam MM; Riyadh MA; Fatema K; Rahman MA; Akhtar N; Ahmed T; Chowdhury MI; Chowdhury F; Calderwood SB; Harris JB; Ryan ET; Qadri F
Clin Vaccine Immunol; 2011 May; 18(5):844-50. PubMed ID: 21346055
[TBL] [Abstract][Full Text] [Related]
17. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh--three years of observation.
Mosley WH; Aziz KM; Rahman AS; Chowdhury AK; Ahmed A
Bull World Health Organ; 1973; 49(4):381-7. PubMed ID: 4604478
[TBL] [Abstract][Full Text] [Related]
18. Effects of undernutrition on infection with Vibrio cholerae O1 and on response to oral cholera vaccine.
Glass RI; Svennerholm AM; Stoll BJ; Khan MR; Huda S; Huq MI; Holmgren J
Pediatr Infect Dis J; 1989 Feb; 8(2):105-9. PubMed ID: 2704600
[TBL] [Abstract][Full Text] [Related]
19. Pasteur oral cholera vaccine: studies of reactogenicity, clinical acceptability and immunogenicity in human volunteers.
Pitisuttitham P; Migasena S; Prayurahong B; Supanaranond W; Suntharasamai P; Supeeranan L; Chantra A; Naksrisook S
Southeast Asian J Trop Med Public Health; 1993 Mar; 24(1):126-9. PubMed ID: 8362286
[TBL] [Abstract][Full Text] [Related]
20. A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh.
Chowdhury F; Khan AI; Harris JB; LaRocque RC; Chowdhury MI; Ryan ET; Faruque AS; Calderwood SB; Qadri F
Pediatr Infect Dis J; 2008 Nov; 27(11):986-92. PubMed ID: 18833030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
